KR100188375B1 - Method for inhibiting gastric acid secretion with benzodioxanes - Google Patents

Method for inhibiting gastric acid secretion with benzodioxanes Download PDF

Info

Publication number
KR100188375B1
KR100188375B1 KR1019980045742A KR19980045742A KR100188375B1 KR 100188375 B1 KR100188375 B1 KR 100188375B1 KR 1019980045742 A KR1019980045742 A KR 1019980045742A KR 19980045742 A KR19980045742 A KR 19980045742A KR 100188375 B1 KR100188375 B1 KR 100188375B1
Authority
KR
South Korea
Prior art keywords
gastric acid
acid secretion
benzodioxanes
inhibiting gastric
inhibiting
Prior art date
Application number
KR1019980045742A
Other languages
English (en)
Inventor
Jaswant Singh Gidda
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of KR100188375B1 publication Critical patent/KR100188375B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019980045742A 1990-05-04 1998-10-29 Method for inhibiting gastric acid secretion with benzodioxanes KR100188375B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/519,388 US5096908A (en) 1990-05-04 1990-05-04 Method of inhibiting gastric acid secretion
KR1019910007204A KR0182791B1 (ko) 1990-05-04 1991-05-03 위산분비억제방법

Publications (1)

Publication Number Publication Date
KR100188375B1 true KR100188375B1 (en) 1999-06-01

Family

ID=24068110

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1019910007204A KR0182791B1 (ko) 1990-05-04 1991-05-03 위산분비억제방법
KR1019980045739A KR100189590B1 (en) 1990-05-04 1998-10-29 Method for inhibiting gastric acid secretion with 8-substituted-2-amino-1,2,3,4-tetrahydronapthalene
KR1019980045740A KR100188373B1 (ko) 1990-05-04 1998-10-29 위산 분비 억제 방법
KR1019980045742A KR100188375B1 (en) 1990-05-04 1998-10-29 Method for inhibiting gastric acid secretion with benzodioxanes
KR1019980045741A KR100188372B1 (ko) 1990-05-04 1998-10-29 위산 분비 억제 방법

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1019910007204A KR0182791B1 (ko) 1990-05-04 1991-05-03 위산분비억제방법
KR1019980045739A KR100189590B1 (en) 1990-05-04 1998-10-29 Method for inhibiting gastric acid secretion with 8-substituted-2-amino-1,2,3,4-tetrahydronapthalene
KR1019980045740A KR100188373B1 (ko) 1990-05-04 1998-10-29 위산 분비 억제 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980045741A KR100188372B1 (ko) 1990-05-04 1998-10-29 위산 분비 억제 방법

Country Status (14)

Country Link
US (1) US5096908A (ko)
EP (1) EP0455510B1 (ko)
JP (1) JPH04270219A (ko)
KR (5) KR0182791B1 (ko)
AT (1) ATE145553T1 (ko)
AU (1) AU640003B2 (ko)
CA (1) CA2040248C (ko)
DE (1) DE69123286T2 (ko)
DK (1) DK0455510T3 (ko)
ES (1) ES2094792T3 (ko)
GR (1) GR3022466T3 (ko)
HU (1) HU217835B (ko)
PH (1) PH27223A (ko)
ZA (1) ZA913363B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229410A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
DE69210959T2 (de) * 1991-11-18 1996-09-26 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamide zur Behandlung von Krankheiten des Zentralnervensystems
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
GB9218113D0 (en) * 1992-08-26 1992-10-14 Lilly Industries Ltd Pharmaceutical compounds
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
CZ285762B6 (cs) * 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
IT1271404B (it) * 1993-08-09 1997-05-28 Hi Chem S P A Derivati ossimici dell'acido formilfenilacetamido-cefalosporanico
FR2712808B1 (fr) * 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ATE287390T1 (de) 1994-10-21 2005-02-15 Nps Pharma Inc Kalzium-rezeptor aktive verbindungen
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
ATE430123T1 (de) 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
CA2338037A1 (en) 1998-07-17 2000-01-27 Synaptic Pharmaceutical Corporation Compounds specific for the human .alpha.1d adrenergic receptor and uses thereof
FR2817257B1 (fr) 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
AU2002218505A1 (en) * 2000-11-30 2002-06-11 Senju Pharmaceutical Co. Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
DE10358004A1 (de) * 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
WO2010021149A1 (ja) * 2008-08-21 2010-02-25 武田薬品工業株式会社 酸分泌抑制スピロ化合物
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906757A (en) * 1959-09-29 Their preparation
US2922744A (en) * 1957-06-26 1960-01-26 Lilly Co Eli Therapeutic processes employing aminobenzodioxane medicaments
DE1668055B2 (de) * 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
AR241161A1 (es) * 1984-07-30 1991-12-30 Merrelll Dow Pharmaceuticals I "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida"
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
EP0306375A1 (fr) * 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
CA1331191C (en) * 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
CN1023402C (zh) * 1988-06-03 1994-01-05 伊莱利利公司 制备5-羟色胺拮抗药的方法

Also Published As

Publication number Publication date
DK0455510T3 (da) 1997-04-28
GR3022466T3 (en) 1997-05-31
KR100189590B1 (en) 1999-06-01
AU640003B2 (en) 1993-08-12
KR0182791B1 (ko) 1999-05-01
CA2040248C (en) 2001-06-19
EP0455510A2 (en) 1991-11-06
DE69123286T2 (de) 1997-04-24
JPH04270219A (ja) 1992-09-25
EP0455510B1 (en) 1996-11-27
PH27223A (en) 1993-05-04
ATE145553T1 (de) 1996-12-15
KR910019615A (ko) 1991-12-19
CA2040248A1 (en) 1991-11-05
HUT60918A (en) 1992-11-30
HU911499D0 (en) 1991-11-28
DE69123286D1 (de) 1997-01-09
ES2094792T3 (es) 1997-02-01
AU7607991A (en) 1991-11-07
HU217835B (hu) 2000-04-28
KR100188372B1 (ko) 1999-06-01
ZA913363B (en) 1993-01-27
EP0455510A3 (en) 1992-05-06
KR100188373B1 (ko) 1999-06-01
US5096908A (en) 1992-03-17

Similar Documents

Publication Publication Date Title
KR100188375B1 (en) Method for inhibiting gastric acid secretion with benzodioxanes
EP0342541A3 (en) Retroviral protease inhibitors
IE851205L (en) Beta-carbolines
ITMI920045A0 (it) Macchina posabinario per l'abbassamento controllato di un binario
IE811650L (en) Stabilized thieno-pyridine compositions
DK322588D0 (da) Cycloalkylamider af 6-substituerede (8beta)-1-alkylergoliner og fremgangsmaade til fremstilling af saadanne forbindelser
EP0521393A3 (en) Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it
YU48512B (sh) Novi glikopeptidi i postupak za njihovu proizvodnju
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
EP0347749A3 (en) Pyrazoloacridone derivatives with anti-tumoral activity
AU8653891A (en) Amino acid analogs as cck antagonists
ZA916918B (en) Amino acid analogs as CCK antagonists.
GR1001203B (el) Μεθοδος παρασκευης της ενωσεως 24r-σκυμνολη.
PH24636A (en) Method of treating heart failure
PL246418A1 (en) Process for preparing n-/3-trifluoromethylphenyl/-n'-propargylpiperazine
EP0528266A3 (en) Method for the production of polyarylethers
ZA927307B (en) Method for treating hypertension
EP0260606A3 (en) Medicament for curing neurotic disturbance or disorder comprising sialocylglycerolipid
IL109227A0 (en) Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof
EP0271447A3 (en) Preventive measures for preventing the "bovine complex respiratory disease" by administering interferon
TW275625B (ko)
UA19166A1 (uk) Гербіцидhа композиція
ZA927034B (en) Novel process for the preparation of anti-ulcer agents.
PL265818A2 (en) Procedure for the production of hydrochloride of 2,4,6-trichloroaniline

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030109

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee